zonisamide has been researched along with levodopa in 24 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (20.83) | 29.6817 |
| 2010's | 10 (41.67) | 24.3611 |
| 2020's | 9 (37.50) | 2.80 |
| Authors | Studies |
|---|---|
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Horiuchi, E; Kanazawa, I; Murata, M | 1 |
| Kohmoto, J; Kondo, T; Miwa, H; Nakanishi, I | 1 |
| Gluck, MR; Granson, H; Santana, LA; Yahr, MD | 1 |
| Murata, M | 2 |
| Kanemaru, A; Kojima, T; Tokashiki, S; Ueda, Y | 1 |
| Hashizume, T; Kaneko, S; Kusaka, H; Morise, S; Nakamura, M; Oki, M; Takenouchi, N; Tsuge, A; Wate, R | 1 |
| Hershey, LA; Irwin, DJ | 1 |
| Hasegawa, K; Iiyama, S; Kosaka, K; Murata, M; Nakamura, M; Odawara, T; Tagawa, M | 1 |
| Bhattacharya, P; Borah, A; Chakrabarty, J; Dutta, A; Mazumder, MK; Paul, R; Phukan, BC | 1 |
| Akamatsu, W; Fujimaki, M; Hatano, T; Hattori, N; Ishikawa, KI; Nojiri, S; Oyama, G; Saiki, S; Takeshige-Amano, H; Ueno, SI; Yamaguchi, A | 1 |
| Nambu, A; Sano, H | 1 |
| Coleman-Jackson, R; Hershey, LA | 1 |
| Iwaki, H; Iwasaki, K; Kawakami, K; Nomoto, M; Tagawa, M | 1 |
| Imbimbo, BP; Lozupone, M; Panza, F; Watling, M | 1 |
| Abe, T; Maruyama, H | 1 |
| Goel, A; Narayan, SK; Sugumaran, R | 1 |
| Kaneko, S; Kusaka, H; Morise, S; Murakami, A; Nakamura, M; Oki, M; Takenouchi, N; Tohge, R; Yakushiji, Y | 1 |
| Maruyama, H; Matsumoto, Y; Nakamura, M; Tsuboi, Y | 1 |
| Jing, XZ; Luo, X; Wang, XP; Yuan, XZ; Zhang, SY | 1 |
| Cai, G; Cai, H; Cui, Y; Feng, T; Lin, F; Su, D; Yan, R | 1 |
| Chiu, SW; Hattori, N; Kashihara, K; Maeda, T; Mishima, T; Nomoto, M; Saiki, H; Shimo, Y; Tsuboi, Y; Watanabe, H; Yamaguchi, T | 1 |
| Ikeda, M; Konishi, O; Mori, E; Orimo, S; Yamada, T | 1 |
6 review(s) available for zonisamide and levodopa
| Article | Year |
|---|---|
[Therapy of Parkinson's disease--up to date].
Topics: Anticonvulsants; Antiparkinson Agents; Carbazoles; Dopamine Agents; Dopamine Agonists; Drug Design; Genetic Therapy; Humans; Isoxazoles; Levodopa; Neuroprotective Agents; Parkinson Disease; Randomized Controlled Trials as Topic; Substantia Nigra; Zonisamide | 2008 |
[Pharmacologic treatment of Parkinson disease].
Topics: Age of Onset; Antiparkinson Agents; Dopamine Agonists; Glutathione; Humans; Isoxazoles; Levodopa; Neuroprotective Agents; Parkinson Disease; Superoxide Dismutase; Zonisamide | 2009 |
Pharmacological Management of Dementia with Lewy Bodies.
Topics: Age Factors; Aged; Anticonvulsants; Antiparkinson Agents; Cholinesterase Inhibitors; Clinical Trials, Phase II as Topic; Clonazepam; Humans; Levodopa; Lewy Body Disease; Melatonin; Randomized Controlled Trials as Topic; Zonisamide | 2019 |
Zonisamide in Parkinson's disease: a current update.
Topics: Dopamine; Humans; Levodopa; Neurodegenerative Diseases; Parkinson Disease; Zonisamide | 2021 |
An Update on Nondopaminergic Treatments for Motor and Non-motor Symptoms of Parkinson's Disease.
Topics: Antiparkinson Agents; Dopamine; Dyskinesias; Humans; Levodopa; Parkinson Disease; Serotonin; Zonisamide | 2023 |
Comparative efficacy and safety of monoamine oxidase type B inhibitors plus channel blockers and monoamine oxidase type B inhibitors as adjuvant therapy to levodopa in the treatment of Parkinson's disease: a network meta-analysis of randomized controlled
Topics: Antiparkinson Agents; Bayes Theorem; Humans; Indans; Levodopa; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Network Meta-Analysis; Parkinson Disease; Randomized Controlled Trials as Topic; Selegiline; Zonisamide | 2023 |
4 trial(s) available for zonisamide and levodopa
| Article | Year |
|---|---|
Zonisamide has beneficial effects on Parkinson's disease patients.
Topics: Aged; Animals; Anticonvulsants; Antiparkinson Agents; Corpus Striatum; Dopamine; Dopamine Agonists; Drug Therapy, Combination; Female; Humans; Isoxazoles; Levodopa; Male; Middle Aged; Motor Activity; Parkinson Disease; Rats; Selegiline; Treatment Outcome; Zonisamide | 2001 |
Adjunct zonisamide to levodopa for DLB parkinsonism: A randomized double-blind phase 2 study.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Levodopa; Lewy Body Disease; Male; Middle Aged; Severity of Illness Index; Treatment Outcome; Zonisamide | 2018 |
Zonisamide improves wearing off in Parkinson's disease without exacerbating dyskinesia: Post hoc analysis of phase 2 and phase 3 clinical trials.
Topics: Antiparkinson Agents; Double-Blind Method; Dyskinesias; Humans; Levodopa; Parkinson Disease; Zonisamide | 2021 |
Efficacy of Adjunctive Therapy with Zonisamide Versus Increased Dose of Levodopa for Motor Symptoms in Patients with Dementia with Lewy Bodies: The Randomized, Controlled, Non-Inferiority DUEL Study.
Topics: Humans; Levodopa; Lewy Body Disease; Zonisamide | 2023 |
14 other study(ies) available for zonisamide and levodopa
| Article | Year |
|---|---|
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
[Effect of zonisamide on resting tremor resistant to antiparkinsonian medication].
Topics: Aged; Aged, 80 and over; Anticonvulsants; Antiparkinson Agents; Humans; Isoxazoles; Levodopa; Male; Middle Aged; Parkinson Disease; Tremor; Zonisamide | 2003 |
Novel dopamine releasing response of an anti-convulsant agent with possible anti-Parkinson's activity.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adrenergic Agents; Animals; Antiparkinson Agents; Behavior, Animal; Carbidopa; Corpus Striatum; Disease Models, Animal; Dopamine; Dopamine Agents; Homovanillic Acid; Isoxazoles; Levodopa; Microdialysis; Oxidopamine; Parkinson Disease; Rats; Zonisamide | 2004 |
Effect of zonisamide co-administration with levodopa on global gene expression in the striata of rats with Parkinson's disease.
Topics: Animals; Anticonvulsants; Antiparkinson Agents; Corpus Striatum; Disease Models, Animal; Drug Therapy, Combination; Gene Expression; Gene Expression Profiling; Isoxazoles; Levodopa; Male; Oligonucleotide Array Sequence Analysis; Oxidopamine; Parkinson Disease; Parkinson Disease, Secondary; Rats; Rats, Wistar; Zonisamide | 2012 |
Zonisamide ameliorates levodopa-induced dyskinesia and reduces expression of striatal genes in Parkinson model rats.
Topics: Animals; Anticonvulsants; Corpus Striatum; Dopamine Agents; Dyskinesia, Drug-Induced; Female; Gene Expression; Isoxazoles; Levodopa; Parkinson Disease; Rats; Rats, Sprague-Dawley; Receptor, Adenosine A2A; Receptor, Cannabinoid, CB1; Receptors, Dopamine D1; Receptors, Dopamine D2; Zonisamide | 2017 |
Zonisamide for DLB parkinsonism: An old drug used in a new context.
Topics: Double-Blind Method; Humans; Levodopa; Lewy Body Disease; Parkinsonian Disorders; Zonisamide | 2018 |
Garcinol, an effective monoamine oxidase-B inhibitor for the treatment of Parkinson's disease.
Topics: Humans; Inflammation; Isoxazoles; Levodopa; Ligands; Molecular Conformation; Molecular Docking Simulation; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Oxidative Stress; Parkinson Disease; Phytochemicals; Phytotherapy; Reactive Oxygen Species; Terpenes; Zonisamide | 2018 |
Zonisamide Administration Improves Fatty Acid β-Oxidation in Parkinson's Disease.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Carnitine; Fatty Acids; Female; Humans; Levodopa; Male; Mental Status and Dementia Tests; Metabolome; Middle Aged; Mitochondria; Oxidation-Reduction; Parkinson Disease; Pilot Projects; Severity of Illness Index; Zonisamide | 2018 |
The effects of zonisamide on L-DOPA-induced dyskinesia in Parkinson's disease model mice.
Topics: Animals; Anticonvulsants; Dyskinesia, Drug-Induced; Levodopa; Male; Mice; Mice, Inbred ICR; Oxidopamine; Parkinsonian Disorders; Treatment Outcome; Zonisamide | 2019 |
Comparison of zonisamide with non-levodopa, anti-Parkinson's disease drugs in the incidence of Parkinson's disease-relevant symptoms.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Symptom Assessment; Treatment Outcome; Zonisamide | 2019 |
Pharmacological management of dementia with Lewy bodies with a focus on zonisamide for treating parkinsonism.
Topics: Brain; Europe; Humans; Levodopa; Lewy Body Disease; Zonisamide | 2021 |
[Effects of switching from dopamine agonists to zonisamide on psychiatric and motor symptoms in patients with Parkinson's disease].
Topics: Dopamine Agonists; Drug Substitution; Hallucinations; Humans; Levodopa; Parkinson Disease; Zonisamide | 2021 |
Zonisamide attenuates the severity of levodopa-induced dyskinesia via modulation of the striatal serotonergic system in a rat model of Parkinson's disease.
Topics: Animals; Anti-Dyskinesia Agents; Antiparkinson Agents; Dyskinesia, Drug-Induced; Female; GABAergic Neurons; Levodopa; Neostriatum; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT1A; Receptor, Serotonin, 5-HT1B; RNA-Binding Proteins; Serotonergic Neurons; Serotonin Agents; Zonisamide | 2021 |
Risk factors for developing dyskinesia among Parkinson's disease patients with wearing-off: J-FIRST.
Topics: Antiparkinson Agents; Catechol O-Methyltransferase; Dopamine Agonists; Dyskinesias; Female; Humans; Levodopa; Parkinson Disease; Quality of Life; Risk Factors; Zonisamide | 2023 |